The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features a real-time scorecard of the Q4 earnings season and new research reports on 16 major ...

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily ... Per the Zacks analyst, Globus Medical is driving impactful innovations from its prolific ...

Globus Medical’s world is about to get a little bigger, as the orthopedic devicemaker moves to acquire Nevro and its ...

Globus Medical (GMED) has agreed to buy Nevro (NVRO) through an all-cash deal valued at around $250M. Read more here.

Globus Medical (NYSE:GMED) announced today that it agreed to acquire chronic pain treatment developer Nevro (NYSE:NVRO).

While Nevro recorded income of around $408 million, Globus Medical's sales at $2.52 billion showed a 60.6% annual rise year over year. Globus anticipates $2.80 billion to $2.90 billion in sales ...

On a stand-alone basis, Globus Medical (GMED) reaffirms guidance for 2025 net sales of $2.66B to $2.69B and fully diluted non-GAAP earnings per share range between $3.40 to $3.50; Revenue ...

Audubon-based Globus Medical has announced its acquisition of California life sciences company Nevro Corp. for $250 million ...

On January 8, 2025, Globus Medical announced preliminary 2024 net sales of $2.52 billion, an increase of 60.6% over prior year on an as-reported basis; and On January 13, 2025, Nevro announced ...

Globus Medical reported preliminary sales projections for 2024 of $2.52 billion, while Nevro expects revenues between $408 million to $409 million. Globus Medical's acquisition of Nevro will ...